In the article by S. Kang et al.,entitled “PCD1, a Novel Gene Containing PDZ and LIM Domains, Is Overexpressed in Several Human Cancers,” which appeared in the September 15, 2000 issue of Cancer Research (pp. 5296–5302), Figure 8C was inadvertently omitted (p. 5301). The correct Figure 8 and the corresponding legend appear below.

In the article by V. V. Levenson et al.,entitled “Pleiotropic Resistance to DNA-interactive Drugs Is Associated with Increased Expression of Genes Involved in DNA Replication, Repair, and Stress Response,” which appeared in the September 15, 2000 issue of Cancer Research (pp. 5027–5030), the figure legend that corresponds to Figure 1 appeared incorrectly (p. 5028). The correct figure legend and the corresponding Figure 1 appear below.

In the article by N. Hansen-Algenstaedt et al.,entitled “Tumor Oxygenation in Hormone-dependent Tumors during VEGFR-2 Blockade, Hormone Ablation, and Chemotherapy,” which appeared in the August 15, 2000 issue of Cancer Research (pp. 4556–4560), the equation expressing pO2 as a function of distance from the vessel wall on p. 4557 appeared incorrectly as:

\[C(x){=}(Q_{\mbox{\textsc{o}}_{2}}/2DS)x^{2}{-}\sqrt{2Q_{\mbox{\textsc{o}}_{2}}(C_{0}{-}C_{min})/DSx{+}C_{0}}\]

The correct equation should read as:

\[C(x){=}(Q_{\mbox{\textsc{\mathrm{o}}}_{2}}/2DS)x^{2}{-}\sqrt{2Q_{\mbox{\textsc{\mathrm{o}}}_{2}}(C_{0}{-}C_{\mathrm{min}})/DS}x{+}C_{0}\]
Fig. 8.
Fig. 8. PCD1 expression analysis by real-time quantitative RT-PCR in the Lightcycler. A, melting curve analysis of the specificity of the PCR amplification product of PCD1 in the Lightcycler. NC, nontemplate control. B, a standard curve established from detection of β-actin levels in the Lightcycler standard samples; 10−1, 10−2,10−3, and 10−4 are regarded as the relative concentrations for the Lightcycler standard samples:10−1×, 10−2×, 10−3×, and 10−4×, respectively. C, PCD1 gene expression levels in tissues from eight colon cancer patients. N,normal colon tissue; PT, primary tumor colon tissue; MET, metastatic liver tissue. The expression data (on the Y axis) have been adjusted by β-actin expression level and are thus relative values. All PCR reactions were performed in duplicate.
View largeDownload slide

PCD1 expression analysis by real-time quantitative RT-PCR in the Lightcycler. A, melting curve analysis of the specificity of the PCR amplification product of PCD1 in the Lightcycler. NC, nontemplate control. B, a standard curve established from detection of β-actin levels in the Lightcycler standard samples; 10−1, 10−2,10−3, and 10−4 are regarded as the relative concentrations for the Lightcycler standard samples:10−1×, 10−2×, 10−3×, and 10−4×, respectively. C, PCD1 gene expression levels in tissues from eight colon cancer patients. N,normal colon tissue; PT, primary tumor colon tissue; MET, metastatic liver tissue. The expression data (on the Y axis) have been adjusted by β-actin expression level and are thus relative values. All PCR reactions were performed in duplicate.

Fig. 8.
Fig. 8. PCD1 expression analysis by real-time quantitative RT-PCR in the Lightcycler. A, melting curve analysis of the specificity of the PCR amplification product of PCD1 in the Lightcycler. NC, nontemplate control. B, a standard curve established from detection of β-actin levels in the Lightcycler standard samples; 10−1, 10−2,10−3, and 10−4 are regarded as the relative concentrations for the Lightcycler standard samples:10−1×, 10−2×, 10−3×, and 10−4×, respectively. C, PCD1 gene expression levels in tissues from eight colon cancer patients. N,normal colon tissue; PT, primary tumor colon tissue; MET, metastatic liver tissue. The expression data (on the Y axis) have been adjusted by β-actin expression level and are thus relative values. All PCR reactions were performed in duplicate.
View largeDownload slide

PCD1 expression analysis by real-time quantitative RT-PCR in the Lightcycler. A, melting curve analysis of the specificity of the PCR amplification product of PCD1 in the Lightcycler. NC, nontemplate control. B, a standard curve established from detection of β-actin levels in the Lightcycler standard samples; 10−1, 10−2,10−3, and 10−4 are regarded as the relative concentrations for the Lightcycler standard samples:10−1×, 10−2×, 10−3×, and 10−4×, respectively. C, PCD1 gene expression levels in tissues from eight colon cancer patients. N,normal colon tissue; PT, primary tumor colon tissue; MET, metastatic liver tissue. The expression data (on the Y axis) have been adjusted by β-actin expression level and are thus relative values. All PCR reactions were performed in duplicate.

Close modal
Fig. 1.
Fig. 1. Colony formation assays for resistance to the indicated drugs in cells lines E14 (□), APH5 () and M125 (▪). Clonogenic survival is plotted as a fraction relative to untreated cells. The drugs and the concentration units are: A, aphidicolin(μ/ml); B, cytarabine (μM); C, hydroxyurea(mM); D, doxorubicin (nM); E, etoposide(μg/ml); F, mafosfamide (μM).
View largeDownload slide

Colony formation assays for resistance to the indicated drugs in cells lines E14 (□), APH5 () and M125 (▪). Clonogenic survival is plotted as a fraction relative to untreated cells. The drugs and the concentration units are: A, aphidicolin(μ/ml); B, cytarabine (μM); C, hydroxyurea(mM); D, doxorubicin (nM); E, etoposide(μg/ml); F, mafosfamide (μM).

Fig. 1.
Fig. 1. Colony formation assays for resistance to the indicated drugs in cells lines E14 (□), APH5 () and M125 (▪). Clonogenic survival is plotted as a fraction relative to untreated cells. The drugs and the concentration units are: A, aphidicolin(μ/ml); B, cytarabine (μM); C, hydroxyurea(mM); D, doxorubicin (nM); E, etoposide(μg/ml); F, mafosfamide (μM).
View largeDownload slide

Colony formation assays for resistance to the indicated drugs in cells lines E14 (□), APH5 () and M125 (▪). Clonogenic survival is plotted as a fraction relative to untreated cells. The drugs and the concentration units are: A, aphidicolin(μ/ml); B, cytarabine (μM); C, hydroxyurea(mM); D, doxorubicin (nM); E, etoposide(μg/ml); F, mafosfamide (μM).

Close modal
©2000 American Association for Cancer Research.
2000